里昂的研究报告指，重新检视了数家内地医药外包(CXO)、中药、创新药物以及医疗服务公司的去年下半年及第四季业绩。整体而言，内地CXO及创新药物表现亮丽，中药维持稳定，而医疗服务公司需要时间恢复。
里昂对医药股投资评级及目标价(表)
股份 | 投资评级 | 目标价(港元)
中国生物制药(01177.HK) | 跑赢大市 | 3.7元 -> 4.8元
翰森制药(03692.HK) | 跑赢大市 | 20.8元 -> 27.8元
康哲药业(00867.HK) | 跑赢大市 | 10.3元 -> 10元
海吉亚医疗(06078.HK) | 跑赢大市 | 20.1元 -> 17.3元
锦欣生殖(01951.HK) | 跑赢大市 | 4.3元 -> 3.8元
固生堂(02273.HK) | 跑赢大市 | 63元 -> 42元
凯莱英(06821.HK) | 跑赢大市 | 63.6元 -> 74.3元
康龙化成(03759.HK) | 跑赢大市 | 18.3元 -> 20.2元
泰格医药(03347.HK) | 跑赢大市 | 34.3元 -> 34.2元
(vc/a)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-07 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.